controlled trial intralesional recombinant interferon-gamma treatment keloidal scarring Clinical histologic findings Interferon-gamma IFN-gamma synthesis collagen fibroblasts vitro synthesis collagen vivo animal models recombinant human IFN-gamma ability keloids Subjects injection mg recombinant human IFN-gamma lesional site diluent lesional site times week weeks Keloids therapy weekly thereafter days final injection biopsies treated sites subjects course treatment reduction size treated site average reduction height vs control sites Lesions recombinant human IFN-gamma alterations epidermis dermis epidermis thinning suprapapillary plates compact hyperkeratosis focal diffuse parakeratosis exocytosis lymphocytes increased quantity mucin dermis diminished quantity thickened collagen bundles active fibroblasts increased number inflammatory cells quantity mucin results feasibility IFN-gamma treatment abnormal fibrosis Dose-ranging studies IFN-gamma true clinical need treatment keloidal scarring 